Esmolol Hydrochloride Injection

Esmolol hydrochloride is a selective (cardioselective) β1 adrenergic receptor blocker with rapid onset and short duration of action. It has no obvious intrinsic sympathomimetic activity or membrane stabilizing effect at therapeutic doses. The elimination half-life after intravenous injection is about 9 minutes. It mainly inhibits β1 adrenergic receptors located in the myocardium, and in large doses, it also has a blocking effect on β2 adrenergic receptors in tracheal and vascular smooth muscle.

The main ingredient of this product is esmolol hydrochloride, and its chemical name is: 4-(3-isopropylamino-2-hydroxypropoxy)phenylpropionic acid methyl ester hydrochloride

This product is a colorless clear liquid.

Used to control ventricular rate in atrial fibrillation, atrial flutter, perioperative hypertension, sinus tachycardia

To control the ventricular rate of atrial fibrillation and atrial flutter, adults should first receive a loading dose of 0.5 mg/kg/min intravenously for about 1 minute, followed by intravenous drip maintenance dose: starting from 0.05 mg/kg/min, if the therapeutic effect is satisfactory after 4 minutes, continue to maintain. If the therapeutic effect is not good, the loading dose can be repeated and the maintenance dose can be increased by 0.05 mg/kg/min. The maximum maintenance dose can be increased to 0.3 mg/kg/min, but doses above 0.2 mg/kg/min have not been shown to bring significant benefits. The immediate control dose for perioperative hypertension or tachycardia is 1 mg/kg intravenously within 30 seconds, followed by 0.15 mg/kg/min intravenously, and the maximum maintenance dose is 0.

Most adverse reactions are mild and transient. The most important adverse reaction is hypotension. Death has been reported when esmolol was used simply to control ventricular rate. Cardiovascular: Symptomatic hypotension (sweating, dizziness) occurred in 12% of patients and asymptomatic hypotension in 25%, of which 63% resolved during dosing and 80% resolved within 30 minutes after discontinuation of the drug. Sweating accompanied hypotension in 10% of patients. Peripheral ischemia occurred in 1%. Pallor, flushing, bradycardia (heart rate <50 beats/min), chest pain, syncope, pulmonary edema, and heart block were reported in less than 1% of patients. In two patients with severe coronary artery disease (posterior inferior myocardial infarction or unstable angina) without supraventricular tachycardia,

It is contraindicated in patients with sinus bradycardia, patients with atrioventricular block of degree I or above, patients with cardiogenic shock, patients with obvious heart failure, patients with bronchial asthma or a history of bronchial asthma, patients with severe chronic obstructive pulmonary disease, patients with refractory heart failure, patients who are allergic to this product.

Drugs that deplete catecholamines, such as reserpine, have additive effects when used in combination with beta-blockers. When this product is used in combination with catecholamine-depleting agents, the occurrence of hypotension or significant bradycardia should be closely observed. They may cause dizziness, syncope or orthostatic hypotension. The combined use of this product and warfarin does not change the blood level of warfarin. The blood concentration of this product seems to increase, but it is not clinically significant. Healthy volunteers were given this product and digoxin intravenously, and the blood concentration of digoxin increased by 10-20% at certain time points. Digoxin does not change the pharmacokinetic characteristics of esmolol. When normal subjects were given this product and morphine intravenously at the same time, there was no significant effect on the blood concentration of morphine, but the steady-state blood concentration of this product increased by 46%. No changes were observed in other pharmacokinetic parameters. <

Sealed and stored in a dry place. Valid for 24 months.

10ml:0.1g

Huarun Shuanghe Limin Pharmaceutical (Ji'nan) Co., Ltd.

• Founded in:

  2001-06-28

• Address:

  No. 1, Limin Road, Mingshui Street, Zhangqiu District, Jinan City, Shandong Province

• Tax NO.:

  91370181163446867C

• Registered Funds:

  23.85 million yuan

• Email:

  Log in to view